Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer : Data from the Prostate Cancer Registry - Bjartell, Anders (Lund University. Department of Translational Medicine, Medical Faculty) ; Lumen, Nicolaas (Universitair Ziekenhuis Gent) ; Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Paiss, Thomas (Urologie team Ulm, Ulm, Germany) ; Gomez-Veiga, Francisco (Instituto de Investigación Biomédica de Salamanca) ; Birtle, Alison (Royal Preston Hospital) ; Kramer, Gero (Medical University of Vienna. Department of Urology) ; Kalinka, Ewa (Polish Mother's Memorial Hospital, Research Institute. Clinic of Oncology) ; Spaëth, Dominique (Centre d'Oncologie de Gentilly, Nancy, France) ; Feyerabend, Susan (Studienpraxis Urologie, Nürtingen, Germany) ; Matveev, Vsevolod (N.N. Blokhin National Cancer Research Center) ; Lefresne, Florence (Janssen Pharmaceutica N.V.. EMEA Oncology) ; Lukac, Martin (Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V) ; Wapenaar, Robert (Janssen-Cilag B.V., Breda, The Netherlands) ; Costa, Luis (Universidade de Lisboa. Oncology Division, Faculdade de Medicina, Hospital de Santa Maria, Instituto de Medicina Molecular) ; Chowdhury, Simon (Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute) ; Universitat Autònoma de Barcelona